Almost all circulating serotonin is contained within platelets in specialised granules. During platelet aggregation serotonin is released.8 In systemic sclerosis platelet activation has been clearly shown.91
SUMMARY Platelet serotonin concentrations were measured in 43 patients with systemic sclerosis, in 11 patients with primary Raynaud's phenomenon, and in 38 normal controls. Patients with the CREST variant (calcinosis, Raynaud's phenomenon, oesophageal dysmotility, sclerodactyly, telangiectasia) had significantly lower platelet serotonin concentrations than normal controls. Patients with diffuse systemic sclerosis had normal platelet serotonin concentrations. In patients with CREST treatment with ketanserin, a specific serotonin antagonist, normalised platelet serotonin concentrations. These data provide further evidence suggesting that in systemic sclerosis, particularly the CREST variant, there is widespread platelet activation.
Microvascular disease is a major feature of systemic sclerosis, with Raynaud's phenomenon occurring in most of the patients. The episodic nature of the ischaemia is suggestive of active vasoconstriction, though structural vessel wall changes have been clearly shown.'
Several observations have implicated serotonin as a possible pathogenetic factor in the development of the microvascular disease. Serotonin can produce digital ischaemia and constriction of isolated human digital arteries.24 In patients with Raynaud's phenomenon vasoconstriction after infusions of serotonin is abnormally prolonged. There is circulatory improvement with serotonin antagonists.5 Furthermore, ketanserin, a specific S2 receptor serotonin antagonist, improves digital blood flow and clinical features in systemic sclerosis.6 7 Almost all circulating serotonin is contained within platelets in specialised granules. During platelet aggregation serotonin is released.8 In systemic sclerosis platelet activation has been clearly shown.91
To study circulating serotonin concentration in systemic sclerosis we developed a simple and reliable method of harvesting intact platelets and adapted our high performance liquid chromatography catecholamime methodi2 to the measurement of serotonin, the serotonin precursor 5-hydroxytryptophan, and the breakdown product 5-hydroxy- 
Results
The concentrations of 5-hydroxytryptophan in the plasma and platelets were similar in all the groups studied. There were no significant age or sex effects on either the plasma or platelet serotonin, 5-hydroxyindoleacetic acid, or 5-hydroxytryptophan. For all the analytes measured there were no significant differences between the patients with primary Raynaud's phenomenon, those with diffuse systemic sclerosis, and the controls. The patients with CREST, however, had significantly lower platelet serotonin concentrations than the controls (1-50 v 3-22 nmoL/109 platelets; p<0-0001). Platelet serotonin concentrations in patients with CREST were also significantly lower than in patients with primary Raynaud's phenomenon (3-46 nmol/109 platelets) and patients with diffuse systemic sclerosis (4-25 nmol/109 platelets); p<0-001 and p=0-007 respectively) (Fig. 2) . Platelet serotonin concentration in the patients with CREST who were treated was significantly higher than in the untreated patients (Table 1) . In those patients whose platelet serotonin was measured before and during treatment there was significant increase in platelet serotonin after ketanserin treatment (p<001) (Fig.   3 ).
The mean plasma serotonin concentration in the patients with CREST was 84 nmol/l (range 8-239 nmol/l), which was greater than for the control subjects (62 nmol/l (range 10-262 nmolI/)). This difference did not reach statistical significance. The There was an inverse relation between platelet serotonin and both plasma serotonin and plasma 5-hydroxyindoleacetic acid. This did not, however, reach significance (p=0-14 and p=0-17 respectively). We have shown that in the CREST variant of systemic sclerosis platelet serotonin is significantly reduced compared with normal controls, patients with primary Raynaud's phenomenon, and patients with diffuse systemic sclerosis. The possible mechanisms involved include a diminished absorption of serotonin precursor, decreased platelet uptake of serotonin, or increased platelet release.
The normal plasma concentration of 5-hydroxytryptophan in the patients with CREST suggests that absorption of serotonin precursors is normal.
It seems unlikely that serotonin uptake and storage are abnormal. Treatment with ketanserin, an S2 receptor antagonist, normalises the platelet serotonin concentration. This effect was present after two weeks of ketanserin treatment and was still present after 12 months' treatment.
Our data can be explained on the basis of widespread platelet activation, aggregation, and serotonin release in patients with CREST. The precise pathogenetic role of platelets in systemic 8 6 7 This study provides further evidence of platelet activation in systemic sclerosis. Increased local concentrations of serotonin may contribute to the microcirulatory impairment, which is a major feature of the CREST syndrome. Our observations suggest that specific S2 serotonin antagonists may be useful in the treatment of digital ischaemia seen in patients with CREST. Significant platelet serotonin Platelet serotonin in systemic sclerosis 589 release does not appear to occur in patients with diffuse systemic sclerosis or with primary Raynaud's phenomenon.
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